Shin Nippon Biomedical Laboratories Balance Sheet Health
Financial Health criteria checks 3/6
Shin Nippon Biomedical Laboratories has a total shareholder equity of ¥30.3B and total debt of ¥26.4B, which brings its debt-to-equity ratio to 87.4%. Its total assets and total liabilities are ¥71.4B and ¥41.1B respectively. Shin Nippon Biomedical Laboratories's EBIT is ¥4.0B making its interest coverage ratio 307.5. It has cash and short-term investments of ¥13.0B.
Key information
87.4%
Debt to equity ratio
JP¥26.44b
Debt
Interest coverage ratio | 307.5x |
Cash | JP¥13.00b |
Equity | JP¥30.25b |
Total liabilities | JP¥41.12b |
Total assets | JP¥71.37b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: YB3's short term assets (¥33.4B) exceed its short term liabilities (¥22.4B).
Long Term Liabilities: YB3's short term assets (¥33.4B) exceed its long term liabilities (¥18.8B).
Debt to Equity History and Analysis
Debt Level: YB3's net debt to equity ratio (44.4%) is considered high.
Reducing Debt: YB3's debt to equity ratio has increased from 50.6% to 87.4% over the past 5 years.
Debt Coverage: YB3's debt is not well covered by operating cash flow (7.2%).
Interest Coverage: YB3's interest payments on its debt are well covered by EBIT (307.5x coverage).